Single-agent divarasib (GDC-6036) in solid tumors with a KRAS G12C mutation
Authors
Sacher, A.LoRusso, P.
Patel, M. R.
Miller, W. H., Jr.
Garralda, E.
Forster, M. D.
Santoro, A.
Falcon, A.
Kim, T. W.
Paz-Ares, L.
Bowyer, S.
de Miguel, M.
Han, S. W.
Krebs, Matthew G
Lee, J. S.
Cheng, M. L.
Arbour, K.
Massarelli, E.
Choi, Y.
Shi, Z.
Mandlekar, S.
Lin, M. T.
Royer-Joo, S.
Chang, J.
Dharia, N. V.
Schutzman, J. L.
Desai, J.
Affiliation
Princess Margaret Cancer Centre, University Health Network, and the Departments of Medicine and Immunology, University of Toronto, TorontoIssue Date
2023
Metadata
Show full item recordAbstract
Background: Divarasib (GDC-6036) is a covalent KRAS G12C inhibitor that was designed to have high potency and selectivity. Methods: In a phase 1 study, we evaluated divarasib administered orally once daily (at doses ranging from 50 to 400 mg) in patients who had advanced or metastatic solid tumors that harbor a KRAS G12C mutation. The primary objective was an assessment of safety; pharmacokinetics, investigator-evaluated antitumor activity, and biomarkers of response and resistance were also assessed. Results: A total of 137 patients (60 with non-small-cell lung cancer [NSCLC], 55 with colorectal cancer, and 22 with other solid tumors) received divarasib. No dose-limiting toxic effects or treatment-related deaths were reported. Treatment-related adverse events occurred in 127 patients (93%); grade 3 events occurred in 15 patients (11%) and a grade 4 event in 1 patient (1%). Treatment-related adverse events resulted in a dose reduction in 19 patients (14%) and discontinuation of treatment in 4 patients (3%). Among patients with NSCLC, a confirmed response was observed in 53.4% of patients (95% confidence interval [CI], 39.9 to 66.7), and the median progression-free survival was 13.1 months (95% CI, 8.8 to could not be estimated). Among patients with colorectal cancer, a confirmed response was observed in 29.1% of patients (95% CI, 17.6 to 42.9), and the median progression-free survival was 5.6 months (95% CI, 4.1 to 8.2). Responses were also observed in patients with other solid tumors. Serial assessment of circulating tumor DNA showed declines in KRAS G12C variant allele frequency associated with response and identified genomic alterations that may confer resistance to divarasib. Conclusions: Treatment with divarasib resulted in durable clinical responses across KRAS G12C-positive tumors, with mostly low-grade adverse events.Citation
Sacher A, LoRusso P, Patel MR, Miller WH, Jr., Garralda E, Forster MD, et al. Single-Agent Divarasib (GDC-6036) in Solid Tumors with a KRAS G12C Mutation. The New England journal of medicine. 2023 Aug 24;389(8):710-21. PubMed PMID: 37611121. Epub 2023/08/23. eng.Journal
New England Journal of MedicineDOI
10.1056/NEJMoa2303810PubMed ID
37611121Additional Links
https://doi.org/10.1056/NEJMoa2303810Type
ArticleLanguage
enae974a485f413a2113503eed53cd6c53
10.1056/NEJMoa2303810
Scopus Count
Collections
Related articles
- Divarasib plus cetuximab in KRAS G12C-positive colorectal cancer: a phase 1b trial.
- Authors: Desai J, Alonso G, Kim SH, Cervantes A, Karasic T, Medina L, Shacham-Shmueli E, Cosman R, Falcon A, Gort E, Guren T, Massarelli E, Miller WH Jr, Paz-Ares L, Prenen H, Amatu A, Cremolini C, Kim TW, Moreno V, Ou SI, Passardi A, Sacher A, Santoro A, Stec R, Ulahannan S, Arbour K, Lorusso P, Luo J, Patel MR, Choi Y, Shi Z, Mandlekar S, Lin MT, Royer-Joo S, Chang J, Jun T, Dharia NV, Schutzman JL, GO42144 Investigator and Study Group, Han SW
- Issue date: 2024 Jan
- KRAS(G12C) Inhibition with Sotorasib in Advanced Solid Tumors.
- Authors: Hong DS, Fakih MG, Strickler JH, Desai J, Durm GA, Shapiro GI, Falchook GS, Price TJ, Sacher A, Denlinger CS, Bang YJ, Dy GK, Krauss JC, Kuboki Y, Kuo JC, Coveler AL, Park K, Kim TW, Barlesi F, Munster PN, Ramalingam SS, Burns TF, Meric-Bernstam F, Henary H, Ngang J, Ngarmchamnanrith G, Kim J, Houk BE, Canon J, Lipford JR, Friberg G, Lito P, Govindan R, Li BT
- Issue date: 2020 Sep 24
- First-in-Human Phase I/IB Dose-Finding Study of Adagrasib (MRTX849) in Patients With Advanced KRAS(G12C) Solid Tumors (KRYSTAL-1).
- Authors: Ou SI, Jänne PA, Leal TA, Rybkin II, Sabari JK, Barve MA, Bazhenova L, Johnson ML, Velastegui KL, Cilliers C, Christensen JG, Yan X, Chao RC, Papadopoulos KP
- Issue date: 2022 Aug 10
- Circulating Tumor DNA Dynamics Reveal KRAS G12C Mutation Heterogeneity and Response to Treatment with the KRAS G12C Inhibitor Divarasib in Solid Tumors.
- Authors: Choi Y, Dharia NV, Jun T, Chang J, Royer-Joo S, Yau KK, Assaf ZJ, Aimi J, Sivakumar S, Montesion M, Sacher A, LoRusso P, Desai J, Schutzman JL, Shi Z, and the GO42144 study group
- Issue date: 2024 Sep 3
- Sotorasib for Lung Cancers with KRAS p.G12C Mutation.
- Authors: Skoulidis F, Li BT, Dy GK, Price TJ, Falchook GS, Wolf J, Italiano A, Schuler M, Borghaei H, Barlesi F, Kato T, Curioni-Fontecedro A, Sacher A, Spira A, Ramalingam SS, Takahashi T, Besse B, Anderson A, Ang A, Tran Q, Mather O, Henary H, Ngarmchamnanrith G, Friberg G, Velcheti V, Govindan R
- Issue date: 2021 Jun 24